Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7269162 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7269162 | EXPERIMENTAL | Participants will receive daily doses of RO7269162 for up to 72 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive daily doses of placebo for up to 72 weeks. |
| Name | Type | Description |
|---|---|---|
| RO7269162 | DRUG | Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks. |
| Placebo | DRUG | Participants will receive daily doses of placebo for up to 72 weeks. |
Inclusion Criteria: * Body Mass Index (BMI) between 18 to 35 kg/m\^2 inclusive at screening * Participants must be either cognitively unimpaired or with a diagnosis of MCI due to AD, according to the National Institute on Aging - Alzheimer's Association (NIA - AA) research framework * Clinical Deme...
Top 20 of 30 competitors
RO7269162 is an investigational small molecule being developed by Roche Holding AG for Alzheimer's disease. It is in Phase 2 clinical development and is being studied in people at risk for or at the prodromal stage of Alzheimer's disease. It has not been approved by the FDA.
RO7269162 is being studied for Alzheimer's disease in individuals who are at risk for or at the prodromal stage of the condition. The Phase 2 trial evaluates its safety and biomarker effects. It is investigational and not approved for any use.
RO7269162 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the ongoing Phase 2 clinical trial for this asset.
RO7269162 is in Phase 2 clinical development. One Phase 2 trial is active and not recruiting, with a planned enrollment of 256 participants. The drug is investigational and has not received FDA approval.
RO7269162 is being evaluated in the Phase 2 trial NCT06402838, titled A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease. The trial is active but not recruiting, with 256 participants across multiple countries.